Literature DB >> 17087787

Antidepressants and sexual dysfunction.

U Werneke1, S Northey, D Bhugra.   

Abstract

OBJECTIVE: Many patients with depression suffer from sexual dysfunction and sexual dysfunction is a recognized side-effect of antidepressants. The aim of this review was to examine the prevalence of psychosexual dysfunction associated with antidepressants, and to review treatment options which are specific to the affected component of sexual functioning and antidepressants.
METHOD: Comprehensive literature review using Medline and Cochrane databases.
RESULTS: Up to 70% of patients with depression may have sexual dysfunction. Tricyclic antidepressants, selective-serotonin reuptake inhibitors and venlafaxine are most and the non-serotonergic antidepressants and duloxetine least likely to produce sexual dysfunction. Pharmacological treatment options include antidepressants less likely associated or 'antidotes' to reverse sexual dysfunction.
CONCLUSION: Sexual dysfunction may be a preventable or treatable side-effect of antidepressants. Patients need routinely to be asked about sexual function to identify problems early. If sexual dysfunction is ignored it may maintain the depression, compromise treatment outcome and lead to non-compliance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17087787     DOI: 10.1111/j.1600-0447.2006.00890.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  26 in total

1.  Acute exercise improves physical sexual arousal in women taking antidepressants.

Authors:  Tierney A Lorenz; Cindy M Meston
Journal:  Ann Behav Med       Date:  2012-06

2.  Fluoxetine prevents 8-OH-DPAT-induced hyperphagia in Fischer inbred rats.

Authors:  Chandra Suma Johnson Miryala; Navin Maswood; Lynda Uphouse
Journal:  Pharmacol Biochem Behav       Date:  2011-01-28       Impact factor: 3.533

Review 3.  Impact of Antidepressant Drugs on Sexual Function and Satisfaction.

Authors:  David S Baldwin; Chris Manson; Magda Nowak
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

4.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

5.  The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management.

Authors:  Angel L Montejo; Laura Montejo; David S Baldwin
Journal:  World Psychiatry       Date:  2018-02       Impact factor: 49.548

6.  A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder.

Authors:  Karen A Tourian; Bruno Pitrosky; S Krishna Padmanabhan; Gregory R Rosas
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 7.  Duloxetine: a review of its use in the treatment of major depressive disorder.

Authors:  James E Frampton; Greg L Plosker
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  Reports of sexual disorders related to serotonin reuptake inhibitors in the French pharmacovigilance database: an example of underreporting.

Authors:  Thierry Trenque; Géric Maura; Emmanuelle Herlem; Catherine Vallet; Elodie Sole; Pascal Auriche; Moustapha Drame
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

Review 9.  The cost effectiveness of pharmacological treatments for generalized anxiety disorder.

Authors:  Ifigeneia Mavranezouli; Nick Meader; John Cape; Tim Kendall
Journal:  Pharmacoeconomics       Date:  2013-04       Impact factor: 4.981

Review 10.  Maintaining sexual health throughout gynecologic cancer survivorship: A comprehensive review and clinical guide.

Authors:  Laura B Huffman; Ellen M Hartenbach; Jeanne Carter; Joanne K Rash; David M Kushner
Journal:  Gynecol Oncol       Date:  2015-11-07       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.